Acrivon (ACRV) Officer Withholds 99 Shares to Cover Taxes After RSU Vesting

Rhea-AI Filing Summary

Acrivon Therapeutics insider sale reported on Form 4. Katharine Peterson, Chief Accounting Officer, recorded a transaction dated 08/14/2025 disclosing a disposition of 99 shares of Acrivon Therapeutics common stock at a price of $1.39 per share. Following the reported sale, Ms. Peterson beneficially owns 4,221 shares, held directly. The filing states the 99 shares were withheld by the issuer to satisfy mandatory tax withholding upon RSU vesting and is signed by an attorney-in-fact on 08/18/2025.

Insights

Corporate Governance Expert

TL;DR: Officer sold shares to cover tax withholding on vested RSUs; holding remains disclosed and transaction appears routine.

The Form 4 shows a small, clearly labeled disposition of 99 shares at $1.39 per share to satisfy tax withholding tied to vested restricted stock units. The reporting person remains identified as Chief Accounting Officer with 4,221 shares beneficially owned post-transaction. This is a standard administrative transaction rather than a purposeful open-market sale, with documentation provided via the Form 4 and an attorney-in-fact signature.

Securities Analyst

TL;DR: Transaction is minor in size and administrative in nature; limited investor impact based on disclosed figures.

The filing documents a disposition of 99 shares at $1.39, leaving 4,221 shares held by the reporting officer. The explanation explicitly states shares were withheld to satisfy mandatory tax withholding upon RSU vesting, indicating the transfer is non-discretionary and routine. No derivative activity or additional transactions are reported on this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Katharine

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		F(1)		99	D	$1.39	4,221	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Adam D. Levy, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the ACRV Form 4 filed by Katharine Peterson disclose?

The Form 4 disclosed a disposition of 99 shares of Acrivon Therapeutics common stock at $1.39 per share dated 08/14/2025.

Why were the 99 shares of ACRV disposed of according to the filing?

The filing states the 99 shares were withheld by the issuer to satisfy mandatory tax withholding upon vesting of restricted stock units.

How many ACRV shares does Katharine Peterson beneficially own after the transaction?

Following the reported transaction, Ms. Peterson beneficially owns 4,221 shares held directly.

What is Katharine Peterson's role at Acrivon Therapeutics as listed on the Form 4?

She is reported as the company's Chief Accounting Officer and an officer of Acrivon Therapeutics.

When was the Form 4 signed and who signed it?

The Form 4 includes a signature block signed by an attorney-in-fact, Adam D. Levy, dated 08/18/2025.